SKYE News

SKYE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Skye Bioscience, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity USA - English APAC - English APAC - Traditional Chinese

Class Action Filing Initiated by Pomerantz LLP Against Skye Bioscience, Inc. – SKYE

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE ALERT: Securities Fraud Class Action Launched Against Skye Bioscience, Inc. - January 16, 2026 Deadline

Class Action Filing Announced by Pomerantz LLP Concerning Skye Bioscience, Inc. – SKYE

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Skye Bioscience, Inc. (SKYE) Investors of January 16, 2026 Deadline

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience Ready to Announce with Confidence?

Levi & Korsinsky Urges Skye Bioscience, Inc. (SKYE) Shareholders to Act Before Lead Plaintiff Deadline January 16, 2026

SKYE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Skye Bioscience, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!